| pubmed-article:19649921 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19649921 | lifeskim:mentions | umls-concept:C0004651 | lld:lifeskim |
| pubmed-article:19649921 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:19649921 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19649921 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:19649921 | pubmed:dateCreated | 2009-8-3 | lld:pubmed |
| pubmed-article:19649921 | pubmed:abstractText | Increasing levels of antibiotic resistance constitutes one of the main challenges in medicine today, and has increased interest in the potential use of alternative antibacterial agents. One of the most interesting 'classes' of novel antibacterials used to combat multidrug-resistant bacteria is bacteriophages, which are viruses that specifically infect and kill bacterial cells. This review discusses the current status of bacteriophage therapy, including the experience of one expert center specializing in this form of treatment. | lld:pubmed |
| pubmed-article:19649921 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19649921 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19649921 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19649921 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19649921 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19649921 | pubmed:issn | 2040-3429 | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:GórskiAndrzej... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:ZimeckiMicha... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:Weber-Dabrows... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:FortunaWojcie... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:Miedzybrodzki... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:BorysowskiJan... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:LetkiewiczS?a... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:LobockaMa?gor... | lld:pubmed |
| pubmed-article:19649921 | pubmed:author | pubmed-author:FilbyGraceG | lld:pubmed |
| pubmed-article:19649921 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19649921 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:19649921 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19649921 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19649921 | pubmed:pagination | 766-74 | lld:pubmed |
| pubmed-article:19649921 | pubmed:meshHeading | pubmed-meshheading:19649921... | lld:pubmed |
| pubmed-article:19649921 | pubmed:meshHeading | pubmed-meshheading:19649921... | lld:pubmed |
| pubmed-article:19649921 | pubmed:meshHeading | pubmed-meshheading:19649921... | lld:pubmed |
| pubmed-article:19649921 | pubmed:meshHeading | pubmed-meshheading:19649921... | lld:pubmed |
| pubmed-article:19649921 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19649921 | pubmed:articleTitle | Bacteriophage therapy for the treatment of infections. | lld:pubmed |
| pubmed-article:19649921 | pubmed:affiliation | Polish Academy of Sciences, Phage Therapy Unit, L Hirszfeld Institute of Immunology and Experimental Therapy, Weigla 12, Wroclaw, Poland. agorski@ikp.pl | lld:pubmed |
| pubmed-article:19649921 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19649921 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:19649921 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19649921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19649921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19649921 | lld:pubmed |
